A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study.

Lhommé C, Vennin P, Callet N, Lesimple T, Achard JL, Chauvergne J, Luporsi E, Chinet-Charrot P, Coudert B, Couette JE, Guastalla JP, Lebrun D, Ispas S, Blumberg J

Gynecologic oncology1 Nov 1999Cited by 29 (Europe PMC)

PMID10525370DOI10.1006/gyno.1999.5538PepBankPUB-10525370

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In advanced or recurrent endometrial cancer, only 16 eligible patients received at least three triptorelin injections, mainly because of progression.
In plain wordsIn endometrial cancer, only 16 patients received at least three triptorelin injections, mainly because the cancer progressed.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableTreatment exposure limited by progression
Study
n = 24
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Measurements
Patients receiving 3 or more injections
16 patients
eligible patients
Source sentences
Summary
Mainly due to progression, only 16 patients received 3 or more injections.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II multicenter study was to assess the efficacy and tolerance of triptorelin (a sustained-release LHRH agonist) in advanced or recurrent endometrial cancer.
Summary · context
A total of 101 monthly intramuscular injections were administered to 24 eligible patients (median number/patient = 3; range 1-12).
Report a problemFND-1052537001
02HumanNon-randomized trialEfficacy outcome
In advanced or recurrent endometrial cancer, median survival among eligible triptorelin recipients was 7.2 months.
In plain wordsIn endometrial cancer, median survival among eligible patients receiving triptorelin was 7.2 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableSurvival
Study
n = 24
Outcome group
Mortality · Cancer
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Measurements
Median survival
7.2 months
eligible patients
Survival range
1 to 36 months
eligible patients
Source sentences
Summary
Median survival for eligible patients was 7.2 months (range: 1-36 months).
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II multicenter study was to assess the efficacy and tolerance of triptorelin (a sustained-release LHRH agonist) in advanced or recurrent endometrial cancer.
Summary · context
A total of 101 monthly intramuscular injections were administered to 24 eligible patients (median number/patient = 3; range 1-12).
Report a problemFND-1052537006
03HumanNon-randomized trialSafety outcome
In advanced or recurrent endometrial cancer, four triptorelin recipients had only grade 1 toxicities possibly related to treatment.
In plain wordsIn endometrial cancer, four patients had only mild toxicities possibly related to triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicablePossibly treatment-related toxicity
Study
n = 24
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Measurements
Patients with toxicity
4 patients
possibly treatment-related
Source sentences
Summary
Only grade 1 toxicities possibly related to the treatment were observed in 4 patients.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II multicenter study was to assess the efficacy and tolerance of triptorelin (a sustained-release LHRH agonist) in advanced or recurrent endometrial cancer.
Summary · context
A total of 101 monthly intramuscular injections were administered to 24 eligible patients (median number/patient = 3; range 1-12).
Report a problemFND-1052537007
04HumanNon-randomized trialEfficacy outcome
In advanced or recurrent endometrial cancer, one evaluable triptorelin recipient had a complete response.
In plain wordsIn endometrial cancer, one evaluable patient receiving triptorelin had a complete response.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableComplete tumor response
Study
n = 23
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Measurements
Complete response
1 patient
evaluable patients
Source sentences
Summary
Among the 23 evaluable patients, 1 complete and 1 partial response (response rate of 8.7%) and 5 disease stabilizations were observed, often of long duration, but never in an irradiated area or after progestogens treatment failure.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II multicenter study was to assess the efficacy and tolerance of triptorelin (a sustained-release LHRH agonist) in advanced or recurrent endometrial cancer.
Summary · context
A total of 101 monthly intramuscular injections were administered to 24 eligible patients (median number/patient = 3; range 1-12).
Report a problemFND-1052537002
05HumanNon-randomized trialEfficacy outcome
In advanced or recurrent endometrial cancer, one evaluable triptorelin recipient had a partial response.
In plain wordsIn endometrial cancer, one evaluable patient receiving triptorelin had a partial response.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicablePartial tumor response
Study
n = 23
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Measurements
Partial response
1 patient
evaluable patients
Source sentences
Summary
Among the 23 evaluable patients, 1 complete and 1 partial response (response rate of 8.7%) and 5 disease stabilizations were observed, often of long duration, but never in an irradiated area or after progestogens treatment failure.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II multicenter study was to assess the efficacy and tolerance of triptorelin (a sustained-release LHRH agonist) in advanced or recurrent endometrial cancer.
Summary · context
A total of 101 monthly intramuscular injections were administered to 24 eligible patients (median number/patient = 3; range 1-12).
Report a problemFND-1052537003
06HumanNon-randomized trialEfficacy outcome
In advanced or recurrent endometrial cancer, the response rate with triptorelin was 8.7% among evaluable patients.
In plain wordsIn endometrial cancer, 8.7% of evaluable patients responded to triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableOverall tumor response
Study
n = 23
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Measurements
Response rate
8.7%
evaluable patients
Source sentences
Summary
Among the 23 evaluable patients, 1 complete and 1 partial response (response rate of 8.7%) and 5 disease stabilizations were observed, often of long duration, but never in an irradiated area or after progestogens treatment failure.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II multicenter study was to assess the efficacy and tolerance of triptorelin (a sustained-release LHRH agonist) in advanced or recurrent endometrial cancer.
Summary · context
A total of 101 monthly intramuscular injections were administered to 24 eligible patients (median number/patient = 3; range 1-12).
Report a problemFND-1052537004
07HumanNon-randomized trialEfficacy outcome
In advanced or recurrent endometrial cancer, five evaluable triptorelin recipients had disease stabilization, often prolonged, but never after progestogen failure or in irradiated areas.
In plain wordsIn endometrial cancer, five triptorelin recipients had stable disease, often prolonged, but never after progestogen failure or in irradiated areas.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableDisease stabilization
Study
n = 23
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · intramuscularAs given in this study (human).
Measurements
Disease stabilization
5 patients
evaluable patients
Source sentences
Summary
Among the 23 evaluable patients, 1 complete and 1 partial response (response rate of 8.7%) and 5 disease stabilizations were observed, often of long duration, but never in an irradiated area or after progestogens treatment failure.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II multicenter study was to assess the efficacy and tolerance of triptorelin (a sustained-release LHRH agonist) in advanced or recurrent endometrial cancer.
Summary · context
A total of 101 monthly intramuscular injections were administered to 24 eligible patients (median number/patient = 3; range 1-12).
Report a problemFND-1052537005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.